The variant, known as B.1.1.7, has a high number of mutations, which has led to concerns that could bypass the immune defences built up by vaccines being rolled out worldwide, a large proportion of which have been made by BioNTech and Pfizer.
However, researchers at BioNTech’s headquarters in Mainz found that a test-tube version of the virus carrying all the new strain’s mutations was neutralised by antibodies in the blood of 16 patients who had received the vaccine in previous trials, half of whom were over 55 years old.
In a paper that has yet to be peer-reviewed, the companies said there was “no biologically significant difference in neutralisation activity” between the results of the lab tests on surrogate versions of the original strain of the coronavirus, sequenced in China last January, and the new variant.
But the authors warned that the “ongoing evolution of Sars-Cov-2 necessitated continuous monitoring of the significance of changes for maintained protection by currently authorised vaccines”.
The test is the first of its kind to be completed by a major vaccine maker, as companies rush to check their jabs hold up against the new variant.
Pfizer and researchers at the University of Texas had already checked it against one of the most worrying changes in the new variant that emerged in the UK and South Africa, in a lab study published earlier this month.
Moderna and Oxford/AstraZeneca, which are both in the process of testing their vaccines, have previously said they expected their jabs to protect against B.1.1.7.
